BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Alesio C, Bellese G, Gagliani MC, Lechiara A, Dameri M, Grasselli E, Lanfrancone L, Cortese K, Castagnola P. The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2+ breast cancer cells. Biol Open 2019;8:bio038323. [PMID: 30967373 DOI: 10.1242/bio.038323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Oyama Y, Shigeta S, Tokunaga H, Tsuji K, Ishibashi M, Shibuya Y, Shimada M, Yasuda J, Yaegashi N. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents. PLoS One 2021;16:e0251079. [PMID: 34161330 DOI: 10.1371/journal.pone.0251079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Han B, Zhang H, Zhu Y, Han X, Wang Z, Gao Z, Yuan Y, Tian R, Zhang F, Niu R. Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes. Aging (Albany NY) 2020;12:13318-37. [PMID: 32649310 DOI: 10.18632/aging.103437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Alendar A, Berns A. Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and disease. Genes Dev 2021;35:1403-30. [PMID: 34725129 DOI: 10.1101/gad.348897.121] [Reference Citation Analysis]
4 Li X, Chen J, Yu Q, Huang H, Liu Z, Wang C, He Y, Zhang X, Li W, Li C, Zhao J, Long W. A Signature of Autophagy-Related Long Non-coding RNA to Predict the Prognosis of Breast Cancer. Front Genet 2021;12:569318. [PMID: 33796128 DOI: 10.3389/fgene.2021.569318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yang ZY, Yang L, Xu CW, Wang XJ, Lei L. An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. Biol Open 2020;9:bio047662. [PMID: 31980423 DOI: 10.1242/bio.047662] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Torres-Martinez Z, Delgado Y, Ferrer-Acosta Y, Suarez-Arroyo IJ, Joaquín-Ovalle FM, Delinois LJ, Griebenow K. Key genes and drug delivery systems to improve the efficiency of chemotherapy. Cancer Drug Resist 2021;4:163-91. [PMID: 34142021 DOI: 10.20517/cdr.2020.64] [Reference Citation Analysis]
7 Wang HC, Chou CL, Yang CC, Huang WL, Hsu YC, Luo CW, Chen TJ, Li CF, Pan MR. Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy. Int J Mol Sci 2019;20:E4087. [PMID: 31438571 DOI: 10.3390/ijms20174087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
8 Novillo A, Fernández-Santander A, Gaibar M, Galán M, Romero-Lorca A, El Abdellaoui-Soussi F, Gómez-Del Arco P. Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer. Front Oncol 2021;11:633233. [PMID: 33981601 DOI: 10.3389/fonc.2021.633233] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Sun Z, Lu Z, Li R, Shao W, Zheng Y, Shi X, Li Y, Song J. Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Immunoautophagy-Related Genes and Tumor Microenvironment. Int J Gen Med 2021;14:5461-73. [PMID: 34526813 DOI: 10.2147/IJGM.S325884] [Reference Citation Analysis]
10 Chang CL, Huang CR, Chang SJ, Wu CC, Chen HH, Luo CW, Yip HK. CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer. Int J Biol Sci 2021;17:1660-70. [PMID: 33994851 DOI: 10.7150/ijbs.56976] [Reference Citation Analysis]